497 Combination therapy with an Aurora B kinase inhibitor AZD1152 and AraC, shows enhanced tumouricidal activity in a preclinical model of acute myeloid leukaemia (AML)
Robert W. Wilkinson(Immunocore (United Kingdom)), Emma L. Anderson, Sarah V. Holt(Pharma Nord (United Kingdom)), John R. Foster(Boston University), Rajesh Odedra
Cited by 0
Related Papers
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
|Journal of Cell Science|2004|344
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
|British Journal of Cancer|2012|111
MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue
|British Journal of Cancer|2017|110
Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint
|Journal of Cell Science|2005|108